valu usd unless otherwis note
portfolio achiev high end guidanc
organ revenu growth ep
establish
continu strong trend medic devic diagnost
fuel organ growth close tougher comp lie ahead
momentum across diversifi portfolio reinforc
ndr may enabl achiev organ growth
year recommend buy share earn
forecast ww revenu ep base
current rate estim fx contribut bp report
revenu growth bp less forecast given
call despit smaller fx benefit chang
revenu estim mid-quart ndr abt cfo reinforc
convict strong fundament posit momentum across
four segment especi medic devic diagnost
believ organ growth two segment abl overcom
shortfal fx
medic devic diagnost segment deliv upsid
revenu estim estim ww revenu
cc organ growth y/i segment nutrit
diabet y/i within vascular rhythm
manag like sourc upsid diagnost success
alin instrument suit evid strong intern
growth revenu increas
assum growth may prove conserv
expect anoth strong quarter libr diabet
experienc strong growth intern due rapid
adopt freestyl libr feedback ada reveal great deal
excit libr well estim ww libr
sale approach sale guidanc
world data present ada lead us conclud
libr sustain growth least next year driven
increas usag type type diabet
expect manag reaffirm guidanc organ revenu
growth non-gaap ep forecast organ revenu growth
rapid diagnost revenu ep
earn call manag estim currenc
benefit revenu growth estim like revis
smaller fx benefit forecast impli report
revenu rang lower
revenu estim approxim due fx
keep ep estim believ organ revenu
growth ep end closer top end guidanc
recommend buy share earn
price prior trade day market close estimate unless otherwis note
cours double-digit ep growth
product cycl refresh medic devic
diagnost cost synergi stj alr capit
deploy acceler debt repay push
abt revenu ep growth ahead sever med-tech
peer revenu estim impli
underli growth ep
estim repres growth
product product approv provid
impetu faster growth medic devic
among signific approv
mr-condit icd septemb mr-condit
crt-d januari receiv approv mr-
condit pacemak februari result
approv rhythm manag product categori
return growth electrophysiolog structur
heart neuromodul among fastest-grow
virtu compet fast-grow end market
shape excit year diagnost
well close alr transact add diagnost
portfolio receiv fda approv
first two instrument new alin platform
laboratori diagnost other
forthcom come month alin suit gain
good traction europ five six instrument
commerci avail
nutrit
adult pediatr market
segment high-single-digit low-double-digit revenu
growth establish pharmaceut factor
drive higher organ revenu growth
bloomberg capit market estim upside/downside/target
arriv price target use sum-of-the-
part analysi valu report segment individu
use respect ev/ebitda multipl blend ev/
ebitda multipl ebitda estim
billion yield target key assumpt underli
valuat cc organ revenu growth
mid-single-digit growth basi point increas
oper margin year addit debt
reduct beyond contempl manag
guidanc price target impli price-to-earnings multipl
ep estim
arriv upsid scenario ev/ebitda multipl
ebitda estim billion key
differ base-cas assumpt mid-
high-single-digit cc organ revenu growth
basi point ebit margin expans year
due higher revenu growth faster realiz cost
synergi integr stj alr faster debt
downsid scenario ebitda
billion key differ base-cas assumpt
low- mid-single-digit cc organ revenu growth
basi point ebit margin expans
year due slower revenu growth slower
realiz cost synergi
preview portfolio achiev high end guidanc
schedul report result wednesday juli host confer call
et forecast ww revenu billion non-gaap ep june
quarter consensu estim billion ww revenu estim
repres organ growth report growth includ fx exclud
diagnost exhibit comparison organ revenu growth
case estim higher revenu growth outsid driven diagnost
medic devic segment see upsid organ growth forecast
come intern diagnost alin devic libr drug-elut
stent sale could also serv sourc upsid
ww revenu estim segment follow
diagnost billion y/i exclud fx rapid diagnost
exhibit revenu model quarter comparison model
estim geographi worldwiderevenu revenu growth excl growth excl revenu growth excl growth revenu growth revenu excl revenu incl worldwiderevenu revenu growth excl growth excl revenu growth excl growth revenu growth revenu excl revenu incl medic suppli devic
issu follow guidanc earn call
organ revenu growth rapid diagnost sale million fx
contribut report growth guidanc produc rang
billion report revenu
medic devic mid- high-single-digit interpret
nutrit low- mid-single-digit interpret
establish pharmaceut double-digit interpret
 dollar appreci major trade currenc past two
month exhibit estim fx contribut basi point revenu growth
instead earlier project basi point convey confer call
basi point differ two estim equat million despit
smaller fx benefit chang revenu estim mid-quart non-
deal roadshow abt cfo brian yoor reinforc convict strong
fundament posit momentum across four segment especi medic
devic diagnost believ organ growth two segment ww
revenu abl overcom shortfal fx
exhibit chang valu dollar major trade currenc
medic devic diagnost segment deliv upsid
medic devic consist
two distinct market segment cardiovascular
neuromodul diabet segment midst power
manag pacemak icd crt-d electrophysiolog three largest
product franchis revenu room upsid estim
product categori exampl could upsid
rhythm
manag revenu growth y/i follow approv mr-condit label
crt-d devic vascular lost market share
valu us chang market market medic suppli devic
competitor launch new drug-elut stent past year receiv fda approv
sierra stent month ahead expect thu icd stent could
drive revenu growth estim growth
also within medic devic diabet experienc strong growth
intern past sever quarter due rapid uptak among consum
freestyl libr feedback american diabet associ annual meet show
great deal excit libr well estim ww libr sale
approach billion sale million guidanc world data
present ada lead us conclud libr sustain growth
least next year driven increas usag type type diabet
base recent compani updat consum world-wide use libr
includ manag estim one million patient
would tri libr end
diagnost success alin instrument suit evid strong
intern growth revenu increas
assum growth may prove conserv alin suit consist
follow instrument alin clinic chemistri alin immunoassay alin
blood plasma screen alin hematolog alin molecular diagnost
develop i-stat alin point diagnost first four instrument
avail europ alin alin approv fda launch
gather momentum europ new assay run alin suit becom
avail custom current european custom transit alin
enter new multi-year contract new custom embrac alin well
accord manag like freestyl libr diabet manag expect alin
multi-year growth driver diagnost segment
expect manag reaffirm guidanc organ
revenu growth non-gaap ep
look ahead second half year-over-year comp get tougher organ
revenu growth rate respect
believ onu sustain organ growth primarili fall two
segment highlight previou section diagnost medic devic therefor
manag commentari outlook segment specif
earn call interest us
forecast organ revenu growth rapid diagnost revenu
billion non-gaap ep earn call manag
estim currenc benefit revenu growth estim like
revis given recent strength dollar smaller fx
benefit forecast impli report revenu rang billion
billion lower revenu estim approxim million
billion keep ep estim revenu estim assum stronger
organ growth abl least partial off-set smaller fx benefit revenu
million instead million
exhibit revenu model
exhibit estim vs consensu june quarter
except epsactualrbcey/yconsensusy/ytot gross sg oper interest incom pre-tax worldwiderevenu revenu growth excl growth excl revenu growth excl growth revenu growth revenu excl revenu incl medic suppli devic
sum-of-the-part valuat abt five major busi base ebitda estim
yield price target individu ev/ebitda multipl use valuat
follow nutrit diagnost cardiovascular neuromodul
diabet establish pharmaceut multipl along
ebitda estim busi give blend ev/ebitda estim
consolid ebitda billion target impli multipl
ep estim peer group evebitda price-to-earnings multipl large-cap med-tech
compani consensu estim price target basi
risk rate price target
face risk typic global diversifi healthcar compani impedi
price target rate includ competit currenc patent litig reimburs
clinic trial risk navig fda prolong econom slump
abbott laboratori one diversifi health care product compani
world product encompass intern brand gener drug devic diagnost
except ep fy dec
